The court (rightly in my view) rejected the patent as being simply an abstract idea, but importantly overturned the "machine or transformation" test that the lower court had devised. I'd say this is good for biotech testing patents (like Myriad's).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.